Structural and functional analysis of the natural JNK1 inhibitor quercetagetin

Journal of Molecular Biology

Volumn 425, Issue 2, 2013, Pages 411-423

  Baek, Sohee ^a,b,c   Kang, Nam Joo ^d,e   Popowicz, Grzegorz M ^a   Arciniega, Marcelino ^a,b   Jung, Sung Keun ^e   Byun, Sanguine ^e,f   Song, Nu Ry ^e,f   Heo, Yong Seok ^g   Kim, Bo Yeon ^h   Lee, Hyong Joo ^f   Holak, Tad A ^a,i   Augustin, Martin ^j   Bode, Ann M ^e   Huber, Robert ^a,b,k,l   Dong, Zigang ^c,e   Lee, Ki Won ^c,f  

^a MAX PLANCK INSTITUTE OF BIOCHEMISTRY   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c Seoul National University   (South Korea)

^d Kyungpook National University   (South Korea)

^e UNIVERSITY OF MINNESOTA   (United States)

^f Seoul National University   (South Korea)

^g Konkuk University   (South Korea)

^h Korea Research Institute of Bioscience and Biotechnology (KRIBB)   (South Korea)

ⁱ JAGIELLONIAN UNIVERSITY   (Poland)

^j PROTEROS BIOSTRUCTURES GMBH   (Germany)

^k CARDIFF UNIVERSITY   (United Kingdom)

^l UNIVERSITY OF DUISBURG ESSEN   (Germany)

more..

Author keywords

JNK1; PI3 K; quercetagetin

Indexed keywords

ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; CENTAUREIDIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN P110; STRESS ACTIVATED PROTEIN KINASE 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BINDING SITE; CANCER INHIBITION; CATALYSIS; CONTROLLED STUDY; COVALENT BOND; CRYSTALLOGRAPHY; DRUG DETERMINATION; DRUG PROTEIN BINDING; DRUG SCREENING; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; FLUORESCENCE; MOLECULAR DOCKING; MOUSE; NONHUMAN; PRIORITY JOURNAL; SKIN CARCINOGENESIS;

EID: 84872117905     PISSN: 00222836     EISSN: 10898638     Source Type: Journal    
DOI: 10.1016/j.jmb.2012.10.019     Document Type: Article

References (27)

1. J.H. Martin, A.A. Mohit, and C.A. Miller Developmental expression in the mouse nervous system of the p493F12 SAP kinase Brain Res. Mol. Brain Res. 35 1996 47 57
2. E.F. Wagner, and A.R. Nebreda Signal integration by JNK and p38 MAPK pathways in cancer development Nat. Rev. Cancer 9 2009 537 549
3. Q. Chang, Y. Zhang, K.J. Beezhold, D. Bhatia, H. Zhao, and J. Chen Sustained JNK1 activation is associated with altered histone H3 methylations in human liver cancer J. Hepatol. 50 2009 323 333
4. X. Ouyang, W.J. Jessen, H. Al-Ahmadie, A.M. Serio, Y. Lin, and W.J. Shih Activator protein-1 transcription factors are associated with progression and recurrence of prostate cancer Cancer Res. 68 2008 2132 2144
5. T. Sakurai, S. Maeda, L. Chang, and M. Karin Loss of hepatic NF-kappa B activity enhances chemical hepatocarcinogenesis through sustained c-Jun N-terminal kinase 1 activation Proc. Natl Acad. Sci. USA 103 2006 10544 10551
6. Z. Dong, M.J. Birrer, R.G. Watts, L.M. Matrisian, and N.H. Colburn Blocking of tumor promoter-induced AP-1 activity inhibits induced transformation in JB6 mouse epidermal cells Proc. Natl Acad. Sci. USA 91 1994 609 613
7. M.R. Young, J.J. Li, M. Rincon, R.A. Flavell, B.K. Sathyanarayana, R. Hunziker, and N. Colburn Transgenic mice demonstrate AP-1 (activator protein-1) transactivation is required for tumor promotion Proc. Natl Acad. Sci. USA 96 1999 9827 9832
8. R. Zenz, H. Scheuch, P. Martin, C. Frank, R. Eferl, and L. Kenner c-Jun regulates eyelid closure and skin tumor development through EGFR signaling Dev. Cell 4 2003 879 889
9. B.Y. Choi, H.S. Choi, K. Ko, Y.Y. Cho, F. Zhu, and B.S. Kang The tumor suppressor p16(INK4a) prevents cell transformation through inhibition of c-Jun phosphorylation and AP-1 activity Nat. Struct. Mol. Biol. 12 2005 699 707
10. J. Hirosumi, G. Tuncman, L. Chang, C.Z. Gorgun, K.T. Uysal, and K. Maeda A central role for JNK in obesity and insulin resistance Nature 420 2002 333 336
11. L.C. Cantley The phosphoinositide 3-kinase pathway Science 296 2002 1655 1657
12. I. Vivanco, N. Palaskas, C. Tran, S.P. Finn, G. Getz, and N.J. Kennedy Identification of the JNK signaling pathway as a functional target of the tumor suppressor PTEN Cancer Cell 11 2007 555 569
13. M.L. Edwards, D.M. Stemerick, and P.S. Sunkara Chalcones: a new class of antimitotic agents J. Med. Chem. 33 1990 1948 1954
14. S. Holder, M. Zemskova, C. Zhang, M. Tabrizizad, R. Bremer, J.W. Neidigh, and M.B. Lilly Characterization of a potent and selective small-molecule inhibitor of the PIM1 kinase Mol. Cancer Ther. 6 2007 163 172
15. D. Ichimatsu, M. Nomura, S. Nakamura, S. Moritani, K. Yokogawa, and S. Kobayashi Structure-activity relationship of flavonoids for inhibition of epidermal growth factor-induced transformation of JB6 Cl 41 cells Mol. Carcinog. 46 2007 436 445
16. Y.S. Heo, S.K. Kim, C.I. Seo, Y.K. Kim, B.J. Sung, and H.S. Lee Structural basis for the selective inhibition of JNK1 by the scaffolding protein JIP1 and SP600125 EMBO J. 23 2004 2185 2195
17. K.M. Comess, C. Sun, C. Abad-Zapatero, E.R. Goedken, R.J. Gum, and D.W. Borhani Discovery and characterization of non-ATP site inhibitors of the mitogen activated protein (MAP) kinases ACS Chem. Biol. 6 2011 234 244
18. 2 + adenylyl imidodiphosphate and inhibitor peptide PKI(5-24) EMBO J. 12 1993 849 859
19. J.R. Sportsman, E.A. Gaudet, and A. Boge Immobilized metal ion affinity-based fluorescence polarization (IMAP): advances in kinase screening Assay Drug Dev. Technol. 2 2004 205 214
20. R.A. Friesner, J.L. Banks, R.B. Murphy, T.A. Halgren, J.J. Klicic, and D.T. Mainz Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy J. Med. Chem. 47 2004 1739 1749
21. R.A. Friesner, R.B. Murphy, M.P. Repasky, L.L. Frye, J.R. Greenwood, and T.A. Halgren Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes J. Med. Chem. 49 2006 6177 6196
22. E.H. Walker, M.E. Pacold, O. Perisic, L. Stephens, P.T. Hawkins, M.P. Wymann, and R.L. Williams Structural determinants of phosphoinositide 3-kinase inhibition by wortmannin, LY294002, quercetin, myricetin, and staurosporine Mol. Cell 6 2000 909 919
23. W. Kabsch Automatic processing of rotation diffraction data from crystals of initially unknown symmetry and cell constants J. Appl. Crystallogr. 26 1993 795 800
24. The CCP4 suite: programs for protein crystallography Acta Crystallogr., Sect. D: Biol. Crystallogr. 50 1994 760 763
25. V.S. Lamzin, and K.S. Wilson Automated refinement of protein models Acta Crystallogr., Sect. D: Biol. Crystallogr. 49 1993 129 147
26. D.E. McRee XtalView/Xfit - a versatile program for manipulating atomic coordinates and electron density J. Struct. Biol. 125 1999 156 165
27. G.N. Murshudov, A.A. Vagin, and E.J. Dodson Refinement of macromolecular structures by the maximum-likelihood method Acta Crystallogr., Sect. D: Biol. Crystallogr. 53 1997 240 255